openPR Logo
Press release

Acromegaly Treatment Market Competitive Developmental and Business Overviews with Top Key Players Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC, Strongbridge Biopharma plc to 2026

01-11-2019 03:22 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Acromegaly Treatment Market

Acromegaly Treatment Market

Acromegaly is a rare disorder caused due to the excess production of growth hormone by the pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually caused by benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can be observed due to ineffective control of growth hormone-secreting cells by hypothalamus. Abnormal enlargement of hands, arms, feet, legs, and head, and gradual changes in facial features such as eye-brow, lower jaw, and nose are visible symptoms of this disorder. Untreated acromegaly leads to serious and life threating complications such as cardiomyopathy and ventricular arrhythmia. Blood test to measure levels of growth hormones or insulin-like growth factor and imaging of tumors through MRI scan and CT scan are commonly used diagnostic approaches to detect acromegaly. Some medications are 90% effective in shrinking tumor, however, success rate of type of treatment varies based on age, health or medical history of patients. According to the American Society of Clinical Oncology (ASCO), 14,230 individuals of the U.S. were diagnosed with pituitary gland tumor in 2017, of which majority are benign tumor. Furthermore, in 2017, the National Organization for Rare Disorders estimated the prevalence rate of acromegaly as 50-70 person per million and 3 new cases occurs per million every year, which is expected to increase the demand for acromegaly treatment market.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1477

Market Driver:

New drugs in the market widens the choice of therapies for doctors and patients. In 2017, Midatech Pharma PLC submitted clinical trial application in human study of Q-Octreotide (MTD201) programme in cancer and acromegaly, and now it has received oral confirmation from Polish regulators for its approval in January 2018. Furthermore, Chiasma Inc’s new oral maintenance therapy for acromegaly treatment named Mycapssa, which has completed an international Phase 3 trial and further conducting an international Phase 3 clinical trial under a protocol accepted by the European Medicines Agency (EMA) for adult patients with acromegaly is also expected to boost growth of acromegaly treatment market over the forecast period. Expiration of drug patents during the forecast period can hamper the market temporarily.

As acromegaly is a non-preventable disease, early detection of the disease will help to cure the disease symptoms. Increasing awareness to differentiate between acromegaly and other disorders like gigantism, Marfan syndrome, and Pachydermoperiostosis, and further detecting the symptoms and diagnosing it will help in propelling the acromegaly treatment market growth. For instance, Acromegaly Awareness Day was celebrated on November 1, 2017 for the first time by World Alliance of Pituitary Organization (WAPO) and Pituitary Network Association to increase awareness on diagnosing the symptoms of this disease without any delay. Some foundation provided financial assistance to medicare patients suffering with acromegaly. For instance, in December 2017, HealthWell Foundation launched a new fund scheme where it provided a fund of US$ 10,000 for a 12-month grant to acromegaly patients who have annual household incomes up to 400 percent of the federal poverty level. Such funding programs will provide financial ease to the patients suffering from acromegaly, which in turn will propel growth of acromegaly treatment market. In 2017, Crinetics Pharmaceuticals, Inc. was awarded Phase IIB Small Business Innovation Research (SBIR) grant of up to US$ 2.8 million from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) for the development of company’s orally-available, non-peptide somatostatin agonist drug candidate, CRN00808 that can be used for the treatment of acromegaly.

Acromegaly Treatment Market - Competitors:

• Pfizer Inc.
• Novartis Pharma AG
• GlaxoSmithKline plc
• Midatech Pharma PLC
• Strongbridge Biopharma plc
• Chiasma Inc
• Aegis Therapeutics LLC
• Amryt Pharma plc
• Antisense Therapeutics Ltd
• Crinetics Pharmaceuticals Inc
• Dauntless Pharmaceuticals Inc
• Ipsen Biopharmaceuticals Inc.

Acromegaly Treatment Market Dynamics:

By Disease Type:
• Ectopic Acromegaly
• Pseudo Acromegaly
By Drug Class:
• Somatostatin Analogs (SSAs)
• Somatuline Depot (Lanreotide)
• Others SSAs
• Dopamine Agonists (DAs)
• Bromocriptine Mesylate (Parlodel)
• Others DAs
• Growth Hormone Receptor Antagonist (GHRAs)
• Somavert (Pegvisomant)
By Route of Administration:
• Oral
• Parenteral
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1477

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acromegaly Treatment Market Competitive Developmental and Business Overviews with Top Key Players Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC, Strongbridge Biopharma plc to 2026 here

News-ID: 1491153 • Views: 302

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Acromegaly

Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights. The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone
Acromegaly Treatment Market Report Up to 2031
Visiongain has published a new report on Acromegaly Treatment Market Report to 2031: Forecasts By Disease Type (Ectopic Acromegaly and Pseudo Acromegaly), By Drug Class (Somatostatin Analogs (SSAs) (Somatuline Depot and Other SSAs), Dopamine Agonists (Bromocriptine Mesylate and Other Dopamine Agonists), and Growth Hormone Receptor Antagonist (Somavert)), By Route of Administration (Oral and Parenteral), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online pharmacies) PLUS COVID-19 Recovery Scenarios. COVID-19 Impact
Global Acromegaly Market Report Forecast to 2027
Acromegaly is a rare hormonal disease that occurs when the body produces too much growth hormone (GH). The excess GH promotes excessive development in the body's bones and soft tissues. The syndrome causes children to grow to very tall heights. They may also have a disproportionately large bone structure. Acromegaly is a condition that mostly affects the arms, legs, and face. Get sample copy of this report @
Global Acromegaly Market Insights, Forecast
Acromegaly is a hormonal disorder that develops when your pituitary gland produces too much growth hormone during adulthood. When this happens, your bones increase in size, including those of your hands, feet and face. Acromegalyusually affects middle-aged adults. The global Acromegaly market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The
Acromegaly Treatment Market Opportunity Analysis, 2018-2026
Acromegaly is a rare disorder caused due to the excess production of growth hormone by the pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually caused by benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can be observed due to ineffective control of growth hormone-secreting cells by hypothalamus. Abnormal enlargement of hands, arms, feet, legs, and head, and gradual changes in facial features such
Global Acromegaly Treatment Market (Ectopic Acromegaly & Pseudo Acromegaly)Diagn …
Global acromegaly treatment market was valued at approximately USD +664.0 Million in 2016 and is expected to generate revenue of around USD +838.0 Million by the end of 2022, growing at a CAGR of around +3.94% between 2017 and 2022. There are various symptoms experienced by the patient like the protruded jaw, increased the size of limbs, the spacing between teeth of lower jaw and others. Conditions like hypertension, diabetes,